Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib IIT of Heat Shock Protein 90 Inhibitor TAS-116 Combined with Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Advanced Breast Cancer Progressing on Palbociclib & Treatment-refractory Solid Tumors with Retinoblastoma Deficiency

NCT05655598 is registered in ClinicalTrials.gov with Brown University as lead sponsor.

NCT NCT05655598
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05655598 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib IIT of Heat Shock Protein 90 Inhibitor TAS-116 Combined with Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Advanced Breast Cancer Progressing on Palbociclib & Treatment-refractory Solid Tumors with Retinoblastoma Deficiency
Lead sponsor
Brown University
Phase
Phase 1
Overall status
Withdrawn
Start date
September 12, 2023
Completion date
August 5, 2024
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, bladder cancer, endometrial cancer, retinoblastoma deficiency, sclc, soft tissue sarcoma, treatment-refractory solid tumors